Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 10/20 | 0.51 |
| ▸ | CES1 | P23141 | 10/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | NAAA | Q02083 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3096367 | 0.87 | CES2 (0.51) | CES2CES1ALDH1A1MAPTLMNA | |
| SCHEMBL27954088 | 0.83 | LMNA (0.51) | CES2CES1LMNANAAA | |
| SCHEMBL3093634 | 0.78 | ALDH1A1 (0.48) | CES2CES1ALDH1A1LMNA | |
| SCHEMBL2120697 | 0.77 | LMNA (0.49) | CES2CES1LMNANAAA | |
| SCHEMBL9095382 | 0.75 | CES2 (0.56) | CES2CES1ALDH1A1MAPTLMNA | |
| SCHEMBL3093028 | 0.74 | ELANE (0.44) | ALDH1A1MAPT | |
| SCHEMBL409199 | 0.73 | LMNA (0.51) | CES2CES1LMNANAAA | |
| SCHEMBL9095301 | 0.73 | CES2 (0.57) | CES2CES1ALDH1A1MAPTLMNA | |
| SCHEMBL11490166 | 0.72 | TSHR (0.58) | CES2CES1ALDH1A1MAPTLMNA | |
| SCHEMBL6025145 | 0.72 | TSHR (0.58) | CES2CES1ALDH1A1MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2203496-B1 | PHOTOLATENT CATALYSTS BASED ON ORGANOMETALLIC COMPOUNDS | BASF SE (DE) | 2018-04-11 | — | — | EP | disclosed |
| US-8318830-B2 | Photolatent catalysts based on organometallic compounds | BASF SE (DE) | 2012-11-27 | — | — | US | disclosed |
| US-20100234485-A1 | PHOTOLATENT CATALYSTS BASED ON ORGANOMETALLIC COMPOUNDS | BASF SE (DE) | 2010-09-16 | — | — | US | disclosed |
| EP-2203496-A1 | PHOTOLATENT CATALYSTS BASED ON ORGANOMETALLIC COMPOUNDS | BASF SE (DE) | 2010-07-07 | — | — | EP | disclosed |
| WO-2009050115-A1 | PHOTOLATENT CATALYSTS BASED ON ORGANOMETALLIC COMPOUNDS | BASF SE (CH) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234485-A1 | PHOTOLATENT CATALYSTS BASED ON ORGANOMETALLIC COMPOUNDS | PUF60, TST, MPST | CES2 996/4885CES1 4029/4885ALDH1A1 1432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.